Ovarian Cancer

There are many misconceptions about genetic testing in cancer, but the SGO crafted a new toolkit to help patients and providers navigate the field.

Stress and depression can alter ovarian cancer tumors, often leading to poorer outcomes.

Optimizing the use of neoadjuvant chemotherapy could improve outcomes for patients with ovarian cancer.

A woman won a lawsuit against Johnson & Johnson, claiming that its baby powder caused her ovarian cancer.

Many female survivors of cancer face sexual pain after treatment, and may not feel comfortable starting a conversation with their health care providers.

Lynparza imrpoved progresion-free survival (PFS) when compared to the placebo group in a phase 3 ovarian cancer trial.

CURE spoke with Scott Richard, M.D., about ovarian cancer recurrence and barriers women may face the second time around.

A new toolkit developed by the Society for Gynecologic Oncology is aimed at increasing awareness about genetic testing for gynecologic cancers.

Mache Seibel discusses the benefits of taking estrogen supplements for women who harbor the BRCA genetic mutation.

A trial testing Zytiga's effectiveness in ovarian cancer was recently halted.

A cohort of patients with ovarian cancer saw survival benefit with niraparib in a recent phase 3 study.

Knowing the risks of ovarian cancer is extremely important. Peter Dottino discusses the risks, symptoms and management of the disease.

Last night's "In Our Genes: An Evening of Storytelling" was an event that not only raised money for research in BRCA-related cancers, but also aimed to raise the spirits of individuals who have been affected by the gene mutation.

Hammonds discusses how she leaves the scary stuff behind and focuses, instead, on the good stuff after ovarian cancer.

September is national Ovarian Cancer Month. My wife died of ovarian cancer at the age of 47. Her final wish was to swim with crocodiles. This is her story.

The NOCC is connecting women who have ovarian cancer to others who are experiencing similar struggles.

The novel agent rucaparib was granted a priority review for the treatment of patients with BRCA-positive advanced ovarian cancer who have received at least two prior lines of chemotherapy.

Neoadjuvant chemotherapy is the best option for some patients with ovarian cancer, according to a recent report.

In honor of Ovarian Cancer Month, it is only appropriate for me to discuss ovarian cancer. "Ovarian cancer" are two of the scariest words in any language for a woman to hear — screening for it at this time is poor and more often than not, by the time it is detected it is too late.

Women who are unable to travel to genetic counselors may be able to reap the same benefits over the phone, according to a recent study.

ASCO and SGO just made new guidelines stating that neoadjuvant chemotherapy is the best first-line treatment for some women with ovarian cancer.

Olga Ivanov talks with CURE about the multiple side effects, including changes in sex drive, that happen after women have risk-reducing surgery.

Allison W. Kurian offers insight on using multigene panel testing to discover breast and ovarian cancer risks that may have otherwise went undetected.

Maintenance treatment with the novel agent niraparib improved progression-free survival (PFS) compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA (gBRCA) mutation or homologous recombination deficiency (HRD).

Testing for BRCA mutations is an important step in developing the treatment plan for patients with breast cancer, says Leslie Randall.

A program was launched to help ovarian cancer survivors combat sexual dysfunction they experience after treatment.

Women who received intraperitoneal chemotherapy after surgery for ovarian cancer had a reduced amount of disease progression when compared with those who received chemotherapy via IV.

According to a recent study, women with the BRCA1 mutation should not delay their pregnancies because their fertility may quickly decline once they enter their 30s.

According to an analysis of the phase 3 GOG-0218 trial, patients who had ovarian cancer and mutations in homologous recombination (HR) genes showed improved survival rates when compared to patients without the mutations.